AEON fails an­oth­er mi­graine tri­al, shares halve as com­pa­ny re­views op­tions

AEON Bio­phar­ma said its bot­u­linum tox­in treat­ment can­di­date failed a Phase 2 mi­graine study at the planned in­ter­im analy­sis. The com­pa­ny’ …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA